What does this score mean?
This publication is not a new randomized treatment study; it is a peer-reviewed review synthesizing multidisciplinary mechanistic literature. The confidence score is high due to a strong and consistent biological framework; it is limited because direct clinical intervention effects were not measured.
What did the study investigate?
It evaluated why obesity, diabetes, chronic kidney disease, and cardiovascular disease frequently progress together, and the role of mitochondrial biology and inter-organ metabolic communication in this shared phenotype.
How was it conducted?
The peer-reviewed review published in Nature Reviews Nephrology brought together human and experimental literature on mitochondrial energy production, fatty acid oxidation, mitophagy, mtDNA integrity, reactive oxygen species, and metabolic signaling molecules in CKM syndrome.
What was found?
The authors approach CKM syndrome not as the sum of separate organ diseases, but as a systems disorder fueled by shared mitochondrial stress and bidirectional organ communication. Signals such as FGF21, GDF15, succinate, and circulating mtDNA are discussed among candidate mediators of this network.
Limitations of the study
This is a review; it does not prove the efficacy of a single intervention. Some mechanisms rely on strong human data, while others are predominantly based on experimental models. General wellness claims such as “strengthening mitochondria” cannot be derived from this review.
What does it mean clinically?
Evaluating the metabolic patient not only through HbA1c or weight, but together with kidney function, hepatic steatosis, muscle capacity, cardiovascular risk, and systemic inflammation is consistent with the CKM approach. However, the efficacy of specific mitochondrial supplements or therapies must be proven separately.
What do we not know yet?
It is not clear which mitochondrial biomarkers will be most useful in daily clinical practice, which targets can be safely modified with drugs, and whether these interventions improve hard clinical endpoints.
Source
Li S, Abel ED, Arany Z, et al. Cardiovascular–kidney–metabolic syndrome as a mitochondrial systems disorder. Nature Reviews Nephrology. 2026. DOI: 10.1038/s41581-026-01127-4. Publication date: September 24, 2026.
Related reading: Mitochondrial Health and Aging · Insulin Resistance and Metabolic Syndrome
Written and medically reviewed by: Dr. Kerem Çağlayan · All Scientific Research
Detailed assessment
Prominent mechanisms
- Impaired fatty acid oxidation and metabolic flexibility
- Decreased mitochondrial biogenesis
- Defective mitophagy and accumulation of damaged organelles
- mtDNA instability and inflammatory signaling
- Stress response molecules such as FGF21 and GDF15
- Bidirectional metabolic communication among heart–kidney–liver–adipose tissue
Conclusion
The CKM approach offers a strong systems biology framework for longevity and functional medicine; however, it does not substitute for clinical evidence for individual “mitochondrial supplements.”
Medical evaluation note: This content has been prepared for the purpose of interpreting scientific data; it is not a personal diagnosis or treatment recommendation.